Search Results
Your search for The ASCO Post Staff,The ASCO Post Staff matches 6160 pages
Showing 1051 - 1100Expert Point of View: Glenn J. Hanna, MD and Sherene Loi, MD, PhD
The ASCO Post asked for comment from Glenn J. Hanna, MD, Director of the Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. Dr. Hanna said it is important to put the findings of KEYNOTE-4121 into context...
Pembrolizumab Plus Chemoradiation Therapy Falls Short in Locally Advanced Head and Neck Cancer
Pembrolizumab plus chemoradiation therapy failed to demonstrate a statistically significant improvement in event-free survival vs chemoradiation therapy alone in patients with locally advanced head and neck squamous cell carcinoma, but favorable numerical trends were demonstrated, according to...
AEGEAN Trial: Addition of Perioperative Durvalumab to Neoadjuvant Chemotherapy in Resectable NSCLC
The addition of perioperative durvalumab to neoadjuvant chemotherapy may be associated with a tolerable surgical safety profile and may not adversely impact surgery in patients with resectable non–small cell lung cancer (NSCLC), according to new findings presented by Mitsudomi et al at the...
Taiwanese Program Shows Potential for Detecting Early-Stage Lung Cancer
Researchers have found that the Taiwan National Lung Cancer Early Detection Program successfully detected 85% of stage 0 and stage I lung cancer cases. The findings by Yang et al were presented at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung...
Modified Classification of Pulmonary Adenocarcinomas May Be More Accurate Than WHO Classification System
A modified adenocarcinoma classification approach may enhance reproducibility and may be an improvement on the existing World Health Organization (WHO) classification system, according to findings presented by Thunnissen et al at the International Association for the Study of Lung Cancer (IASLC)...
Aki Morikawa, MD, PhD, on Brain Metastases: New Findings on Predictive Drug Testing
Aki Morikawa, MD, PhD, of the University of Michigan, and her team explored the use of patient-derived organoids from breast cancer brain metastases to evaluate drug sensitivities in a clinically meaningful time frame. Along with molecular profiling, she says, this method may further personalize...
Montefiore Einstein Comprehensive Cancer Center Awarded Comprehensive Designation From the NCI
The newly renamed Montefiore Einstein Comprehensive Cancer Center (MECCC) has been awarded comprehensive designation by the National Cancer Institute (NCI) of the National Institutes of Health. As a result, MECCC was awarded a 5-year, $20 million Cancer Center Support Grant to advance the...
FDA Approves New Multiple Myeloma Combination Therapy
On September 11, the U.S. Food and Drug Administration (FDA) approved motixafortide (Aphexda) in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. Motixafortide is...
Study Questions Role of Extended Pleurectomy Decortication in Patients With Mesothelioma
Extended pleurectomy decortication combined with chemotherapy was associated with worse survival outcomes, a higher incidence of serious adverse events, and a diminished quality of life in patients with resectable mesothelioma compared with platinum and pemetrexed chemotherapy alone, according to...
NSCLC: Osimertinib Plus Chemo vs Osimertinib Alone
Osimertinib plus chemotherapy may have demonstrated a statistically significant and clinically meaningful progression-free survival benefit in patients with advanced non–small cell lung cancer (NSCLC) compared with osimertinib alone, according to new findings presented by Jänne et al at the...
EGFR Tyrosine Kinase Inhibitors vs Durvalumab in EGFR-Mutated NSCLC: Impact on Survival
Researchers have discovered that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors may improve survival outcomes after treatment with chemoradiation in patients with stage III EGFR-mutated non–small cell lung cancer (NSCLC) compared to the PD-L1 inhibitor durvalumab, according to...
Atrium Health Levine Children’s Expands to Include New Outpatient Center for Cancer and Blood Disorders
Atrium Health Levine Children’s is expanding its commitment to deliver oncology, hematology, and cellular therapies care to patients across the region, the United States, and the world with the recent opening of its completely reimagined outpatient center. The Torrey Hemby Center for Cancer and...
Ishwaria Subbiah, MD, MS, Joins SCRI as Executive Director, Cancer Care Equity and Professional Wellness
Sarah Cannon Research Institute (SCRI) recently announced the appointment of Ishwaria Subbiah, MD, MS, as Executive Director, Cancer Care Equity and Professional Wellness. In this role, Dr. Subbiah will focus on reducing cancer outcomes disparities and diversifying clinical trial participation...
Wei Wu, MD, PhD, on Lung Cancer: Deep Learning as a Tool for Identifying Drug-Tolerant Persister Cells
Wei Wu, MD, PhD, of the University of California, San Francisco, discusses new findings that suggest his team’s deep learning neural network model may be able to identify subpopulations of patients with lung cancer who have YAP1-activated tumors and drug-tolerant persister cells. These patients may ...
Crystal S. Denlinger, MD, FACP, Named New Chief Executive Officer of NCCN
The National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading academic cancer centers—announced Crystal S. Denlinger, MD, FACP, as incoming Chief Executive Officer (CEO). Dr. Denlinger—who is currently NCCN’s Senior Vice President, Chief Scientific Officer—will lead the ...
ASCO Remembers Chemotherapy Pioneer and Karnofsky Award Recipient Irwin H. Krakoff, MD
ASCO is saddened by the passing of Irwin H. Krakoff, MD, on August 9, 2023, at the age of 100. He is remembered as one of the founding fathers of modern chemotherapy. Dr. Krakoff was born on July 20, 1923, in Columbus, Ohio. He attended The Ohio State University, earning his bachelor’s degree in...
Thomas J. Herzog, MD, Takes Office as President of the GOG Foundation, Inc
Thomas J. Herzog, MD, took office as President of the GOG Foundation (GOG-F, formerly the Gynecologic Oncology Group), Inc, on July 20, 2023, at the NRG Oncology Summer Meeting. Former GOG-F President, Larry J. Copeland, MD, passed the presidential gavel to Dr. Herzog at the GOG-F Board of...
Jesse M. Ehrenfeld, MD, MPH, Inaugurated as President of the AMA
Jesse M. Ehrenfeld, MD, MPH, was sworn in as the 178th President of the American Medical Association (AMA), the nation’s premier physician organization, on June 13, 2023. At his inauguration, Dr. Ehrenfeld spoke about health inequities and injustices: “The AMA has made tremendous strides in recent ...
Vivek Subbiah, MD, Joins SCRI to Advance Early-Phase Clinical Research
Sarah Cannon Research Institute (SCRI) recently announced that Vivek Subbiah, MD, has joined the organization as Chief, Early-Phase Drug Development. In his role, Dr. Subbiah will oversee SCRI’s nine drug development units and lead the expansion of early-phase capabilities and programs across the...
Nicholas Petrelli, MD, FACS, Receives Lifetime Achievement Award From Tulane University Medical School
Nicholas Petrelli, MD, FACS, Bank of America Endowed Medical Director of ChristianaCare’s Helen F. Graham Cancer Center & Research Institute in Newark, Delaware, has received the Lifetime Achievement Award from Tulane University School of Medicine in New Orleans. Dr. Petrelli is a 1973...
Radiation Exposure From Medical Imaging in Pediatric Patients With Down Syndrome
Pediatric patients with Down syndrome may undergo almost 10 times as many medical imaging examinations as other pediatric patients, potentially exposing them to more ionizing radiation, according to a recent study published by Marlow et al in PLOS ONE. Background Ionizing radiation is present in...
Vitamin C and D Supplements for Patients With AML Undergoing Intensive Chemotherapy
Patients with acute myeloid leukemia (AML) who received vitamin C and D supplements during intensive chemotherapy had lower rates of complications such as infections, bleeding, and inflammation compared with patients who did not receive the supplements, according to a recent study published by...
Efficacy of the 9-Valent HPV Vaccine: 10-Year Follow-up
New 10-year follow-up data were published by Restrepo et al in Pediatrics on girls and boys who received a three-dose regimen of the 9-valent human papillomavirus (HPV) vaccine between the ages of 9 and 15. The long-term follow-up study was conducted from 2009 through 2021 across 13 countries and 5 ...
Aaron C. Tan, PhD, MBBS, on Circulating Tumor DNA: Early Biomarker of Therapeutic Response in Phase I Trials
Aaron C. Tan, PhD, MBBS, of the National Cancer Centre Singapore, discusses new findings on early evaluation of circulating tumor DNA via low-pass whole-genome sequencing. The results of his study suggest this method may represent an early pharmacodynamic biomarker of therapeutic response...
Enhanced Recovery Program May Be Effective at Reducing Opioid Use After Pancreatic Cancer Surgery
Improving hospital care pathways may help reduce inpatient opioid use by 50% and cut the median opioid prescription volumes at discharge to zero in patients undergoing pancreatic cancer surgery, according to a recent study published by Boyev et al in JAMA Surgery. The new findings could help reduce ...
SNMMI Provides New Consensus Statement on LuPSMA Therapy
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has provided standardized guidance on the selection and management of patients receiving lutetium-177–labeled PSMA-617 (LuPSMA) radionuclide therapy for metastatic castration-resistant prostate cancer, according to a new consensus...
Nikhil Munshi, MD, on Multiple Myeloma: Data From the CARTITUDE-1 Study of Ciltacabtagene Autoleucel
Nikhil Munshi, MD, of Dana-Farber Cancer Institute, discusses the final safety and efficacy results from the phase Ib/II CARTITUDE-1 trial of ciltacabtagene autoleucel. This CAR T-cell therapy targets B-cell maturation antigen in patients with relapsed or refractory multiple myeloma. Longer median...
Can AI Assessment of Screening Mammograms Offer Similar Accuracy to Human Readers?
A commercially available artificial intelligence (AI) algorithm may perform comparably to human readers at assessing screening mammograms, according to a recent study published by Chen et al in Radiology. False-positive interpretations on screening mammograms can result in women without cancer...
Examining Disparities in Endometrial Cancer Outcomes Among Black Patients
Black patients with stage IA low-grade endometrioid endometrial carcinoma may be less likely to undergo a hysterectomy and survive their cancer than White patients with the same type of cancer, according to a recent study published by Taylor et al in Gynecologic Oncology. Background “We’ve known...
23andMe Granted FDA 510(k) Clearance to Report Additional BRCA Variants
23andMe has announced that the company has received a U.S. Food and Drug Administration (FDA) 510(k) clearance to expand its existing BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report. The clearance allows 23andMe to report an additional 41 variants in the BRCA1 and BRCA2 genes known to be ...
Statins May Be Linked to Lower Risk of Colorectal Cancer in Patients With Ulcerative Colitis
Cholesterol-lowering statins may reduce colorectal cancer incidence and mortality in patients with ulcerative colitis, according to a recent study published by Sun et al in eClinicalMedicine. The findings also suggested that statin use may be associated with a lower risk of all-cause mortality in...
Strategies to Predict Immunotherapy Benefit Among Patients With Advanced Colorectal Cancer
Researchers have identified new strategies to help physicians predict which patients with advanced colorectal cancer may benefit from immunotherapy, according to a recent study published by Saberzadeh-Ardestani et al in Clinical Cancer Research. The findings demonstrate the potential of using...
New Data on a Response Biomarker for Dovitinib in Patients With RCC
A new report published by Knudsen et al in PLOS ONE focused on the clinical validation of a drug response predictor (DRP) biomarker algorithm for dovitinib, a receptor tyrosine kinase inhibitor of VEGFR1–3, PDGFR, FGFR1/3, c-KIT, FLT3, and topoisomerase 1 and 2. Data showed that the DRP-dovitinib...
Improving Nutrition Guidance May Optimize Fertility Treatments for Female Cancer Survivors
Researchers have identified potential strategies to promote healthy dietary habits in female cancer survivors with fertility challenges, according to a recent study published by Klobodu et al in Integrative Cancer Therapies. Background Cancer may increase the risk of infertility in young female...
Risk Factors for Melanoma Among Individuals Living in Atlantic Canada
Investigators in Canada may have uncovered the factors contributing to the higher risk of melanoma among individuals living in Atlantic regions, according to a recent study published by Lagacé et al in Cancers. These findings may provide insights into effective strategies for skin cancer...
Time Gaps May Be Critical Parameters When Sparing Skin During FLASH Radiation Therapy
Researchers have demonstrated that, in preclinical models, multiple beams and intervals in delivery during FLASH radiation therapy may compromise the skin-sparing effects of the technique, according to a novel study published by Mascia et al in the International Journal of Radiation Oncology •...
Edoxaban Taken for 12 Months May Improve Outcomes in Patients With Cancer and Isolated Distal Deep Vein Thrombosis
Researchers have found that 12 months of the oral factor Xa inhibitor edoxaban may be superior to 3 months for the reduction of thrombotic events in patients with cancer and distal deep vein thrombosis, according to new findings presented by Yamashita et al at the European Society of Cardiology...
New Clinical Trial Seeks to Reduce Cardiovascular Damage in Patients Undergoing Anticancer Therapy for Breast Cancer
Researchers have launched a new clinical trial examining the effectiveness of behavioral and psychological interventions at reducing cardiovascular damage caused by anticancer therapies in patients with breast cancer. Background Breast cancer—the most common cancer type in the European...
Are Cannabinoids Safe and Effective for Reducing Symptoms in Pediatric Patients With Cancer?
Investigators have revealed that there may be a lack of evidence to inform the dosing, safety, and efficacy of cannabinoids for managing symptoms in pediatric patients with cancer, according to a recent systematic review and meta-analysis published by Chhabra et al in Cancer. Background Although...
Optimizing Tobacco Cessation Treatment With Lung Cancer Screenings
The Program for Lung Cancer Screening and Tobacco Cessation trial tested different adaptive interventions based on the evidence-based Tobacco Longitudinal Care (TLC) program, in part to learn how best to incorporate TLC into annual lung cancer screening as a smoking cessation standard. The findings ...
FDA Approves Luspatercept-aamt as First-Line Treatment for Adult Patients With Lower-Risk MDS and Anemia Who May Require Transfusions
On August 28, the U.S. Food and Drug Administration (FDA) approved luspatercept-aamt (Reblozyl) to treat anemia in adult patients with very low– to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell transfusions and who have not received previous...
How Guideline-Concordant Are Cancer Treatment Recommendations From ChatGPT?
Researchers have found that about one-third of treatment recommendations from the artificial intelligence (AI) model ChatGPT 3.5 were nonconcordant with the NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®), according to a recent study published by Chen et al in JAMA Oncology. The...
Study Shows Potential of Cabozantinib to Treat Patients With Advanced Neuroendocrine Tumors
An interim analysis of the CABINET trial has shown that the phase III pivotal trial has met its primary endpoint, according to a press release from the Alliance for Clinical Trials in Oncology. Cabozantinib demonstrated statistically significant and clinically meaningful improvements in...
Rural Patients With Cancer: Receipt of Surgical Care at High- vs Low-Volume Hospitals
Patients with cancer who live in rural Pennsylvania counties appear to know that they may have better outcomes if they receive their cancer surgery at a hospital that performs a high volume of those procedures—but many still opt for lower-volume hospitals closer to home when their cancer is likely...
Adherence to Mediterranean Lifestyle May Be Associated With Lower Risk of All-Cause and Cancer Mortality
Patients who adhere to a Mediterranean lifestyle may have a lower risk of all-cause and cancer mortality, according to a recent study published by Maroto-Rodriguez et al in Mayo Clinic Proceedings. The new findings also indicated that patients who followed the lifestyle’s emphasis on rest,...
Short-Term Use of Immunosuppressants May Not Be Linked to Increased Cancer Risk in Patients With Ocular Inflammatory Diseases
Short-term use of immunosuppressants in patients with ocular inflammatory disease may not be associated with an increased risk of developing cancer, according to a recent study published by Buchanich et al in BMJ Oncology. Background The Systemic Immunosuppressive Therapy for Eye Diseases (SITE)...
Cardiorespiratory Fitness in Youth May Be Associated With a Lower Risk of Nine Cancer Types
Partaking in cardiorespiratory fitness in youth may be associated with up to a 40% lower risk of developing nine cancer types later in life, according to a recent study published by Onerup et al in the British Journal of Sports Medicine. Background Cardiorespiratory fitness—including sustained...
The Future Priorities of the National Cancer Institute
Fifty-two years ago, President Richard Nixon signed the National Cancer Act of 1971 into law, which established the National Cancer Institute (NCI) in its current form. At the time, the budget was $1.6 billion. Today, it is $7.8 billion, $4.5 billion less than the amount needed to keep up with...
Novel Targeted Therapy Combination May Be an Effective First-Line Option for Gastric or Gastroesophageal Junction Adenocarcinoma
Researchers have found that the novel targeted therapy zolbetuximab in combination with a standard chemotherapy may extend survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma and overexpression of the claudin-18 isoform 2 protein (CLDN18.2), according to a novel...
Sacituzumab Govitecan-hziy Continues to Show Benefit in Patients With Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
The antibody-drug conjugate sacituzumab govitecan-hziy continued to demonstrate superior benefit for patients with hormone receptor–positive, HER2-negative metastatic breast cancer when compared with standard chemotherapy, according to the final analysis of the phase III TROPiCS-02 study published...
